热门资讯> 正文
Vor Bio宣布7500万美元私募
2026-03-27 20:20
- Vor Bio (VOR) said on Friday it had entered a securities purchase agreement to sell 5.34M shares at $14.05 each in a private placement, for gross proceeds of about $75M.
- The private placement is expected to close on or about March 30, 2026.
- The financing is led by new investor TCGX.
- The net proceeds from the offering will be used for advancing telitacicept’s clinical program, including ongoing global Phase 3 trials in myasthenia gravis and primary Sjögren's disease, along with business development and general corporate purposes.
- Shares +4.87%.
More on Vor Biopharma
- Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
- Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Seeking Alpha’s Quant Rating on Vor Biopharma
- Historical earnings data for Vor Biopharma
- Financial information for Vor Biopharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
